Holen Sie sich die Stockscreener-App
10.07
6.56%
0.62
Handel nachbörslich:
10.07
Biohaven Ltd Aktie (BHVN) Neueste Nachrichten
BHVN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
Biohaven reports opakalim epilepsy trial data ahead of R&D day By Investing.com - Investing.com Australia
Biohaven shares clinical data on epilepsy drug opakalim - StreetInsider
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile - PR Newswire
Trading Systems Reacting to (BHVN) Volatility - Stock Traders Daily
BofA Securities Maintains Biohaven(BHVN.US) With Hold Rating, Maintains Target Price $12 - Moomoo
BHVN Stock Chart | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
BHVN Stock Price, Quote & Chart | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
BTIG Reiterates Biohaven (BHVN) Buy Recommendation - MSN
[SCHEDULE 13G/A] Biohaven Ltd. Amended Passive Investment Disclosure - Stock Titan
BHVN Stock Price Prediction 2025-2026 | Biohaven Pharmaceutical Holding Co Ltd Forecast - 24/7 Wall St.
Biohaven (BHVN) Narrows Loss and Adds Shelf Registration Is Its Capital Strategy Evolving? - simplywall.st
Biohaven Ltd. (BHVN) Receives a Hold from Bernstein - The Globe and Mail
BHVN Technical Analysis | Trend, Signals & Chart Patterns | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $18 - Moomoo
Morgan Stanley Cuts Price Target on Biohaven to $18 From $21, Keeps Overweight Rating - Moomoo
TradingKey - TradingKey
Biohaven Ltd. Stock 12‑Month Price Target Cut to $22.19, Implies 141% Upside - TradingView
Biohaven (BHVN) Valuation Check After Q1 Results And New Shelf Registration - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright reiterates Biohaven stock rating ahead of trial By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Biohaven stock rating ahead of trial - Investing.com
Biohaven: Hold Rating Reiterated as Clinical and Competitive Uncertainties Persist; Price Target Maintained at $10 - TipRanks
H.C. Wainwright Maintains Biohaven(BHVN.US) With Hold Rating, Maintains Target Price $10 - Moomoo
How Biohaven Ltd. (BHVN) Affects Rotational Strategy Timing - Stock Traders Daily
MSN Money - MSN
Biohaven Ltd. (BHVN) upgraded to buy: Here's why - MSN
Biohaven (BHVN) Is Up 9.1% After Narrower Q1 Loss And New Mixed Shelf RegistrationWhat's Changed - Yahoo Finance
Biohaven Warns of Broad Operational, Financial and Market Risks, Affirms Overall Risk Profile Matches Prior 10-K Disclosures - TipRanks
Biohaven Expands At-The-Market Equity Offering Program - TipRanks
Biohaven (NYSE: BHVN) adds $350.0 million at-the-market share program - Stock Titan
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why - Yahoo! Finance Canada
Biohaven: Buy Rating Reiterated as Analyst Sees Multiple Pipeline Catalysts and Maintains $21 Price Target - TipRanks
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $22 - Moomoo
A Quick Look at Today's Ratings for Biohaven(BHVN.US), With a Forecast Between $12 to $30 - Moomoo
Biohaven Ltd. Q1 2026 Financial Report: Key Highlights, Financial Statements, and Business Overview - Minichart
RBC Cuts Price Target on Biohaven to $22 From $23, Keeps Outperform, Speculative Risk - marketscreener.com
BofA Securities Maintains Biohaven(BHVN.US) With Hold Rating, Cuts Target Price to $12 - Moomoo
A Look At Biohaven (BHVN) Valuation After Narrower Q1 Loss And New Pivotal Trial And Funding Plans - Yahoo Finance
Biohaven Price Target Trimmed to $12 as Analyst Maintains Hold Amid Balanced Pipeline Upside and Financing Risks - TipRanks
MSN - MSN
Biohaven (BHVN) Is Up 5.7% After Narrower Q1 Loss And Pivotal Trial Plans – Has The Bull Case Changed? - simplywall.st
Biohaven Shareholders Back Board, Auditor and Executive Pay - TipRanks
Biohaven files for offering of up to $350 million common sharesSEC filing - marketscreener.com
Biohaven Ltd. (NYSE: BHVN) expands ATM program to $350M for common shares - Stock Titan
Biohaven (NYSE: BHVN) trims Q1 2026 loss and raises $178.9M - Stock Titan
Biohaven Pharma (BHVN) files mixed shelf - StreetInsider
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):